Obstetric outcomes in patients with primary thrombotic and obstetric antiphospholipid syndrome and its relation to the antiphospholipid antibody profile

Abstract

Introduction: Previous studies suggested different obstetric outcomes between patients with thrombotic or obstetric antiphospholipid syndrome, but the data are inconclusive. Aims: To investigate obstetric outcomes and their relation to the antiphospholipid antibody profile in primary thrombotic or obstetric antiphospholipid syndrome patients and compare those to a control population. Materials and methods: A retrospective single-centre study on a cohort of 30 pregnant women with primary antiphospholipid syndrome treated at Karolinska University Hospital Solna, Sweden between 2000 and 2016. The pregnancy outcomes were compared to the outcomes of all pregnancies in Stockholm County during the same period. Results: Preeclampsia (p < 0.001), low birth weight at delivery (p = 0.001), Apgar < 7 at 5 minutes (p < 0.001) and small infants (p < 0.001) were more common in antiphospholipid syndrome patients compared to controls. Obstetric antiphospholipid syndrome patients had a higher incidence of small infants (p = 0.023), lower birth weight (p = 0.013) and infants born with complications (p=0.004) compared to thrombotic antiphospholipid syndrome. Mothers with triple antibody positivity had a higher incidence of preeclampsia (p = 0.03), preterm delivery (p = 0.011), small infants (p=0.002) and infants born with complications (p = 0.012). Conclusions: Patients with primary antiphospholipid syndrome, especially those with obstetric antiphospholipid syndrome and triple antibody positivity, are at higher risk for adverse pregnancy outcomes, even under antithrombotic treatment. More frequent antenatal controls in high-risk patients can further improve outcomes.

Keywords

Antiphospholipid syndrome antiphospholipid antibodies pregnancy preeclampsia small for gestational age birth weight

Get full access to this article

View all access options for this article.

References

Chighizola

Andreoli

de Jesus

Banzato

Pons-Estel

Erkan

. The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: A critical review of the literature. Lupus 2015; 24: 980–984.

Cervera

Serrano

Pons-Estel

et al.

Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients. Annals of the Rheumatic Diseases 2015; 74: 1011–1018.

Miyakis

Lockshin

Atsumi

et al.

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.

Simchen

Dulitzki

Rofe

et al.

High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome. Acta Obstet Gynecol Scand 2011; 90: 1428–1433.

Saccone

Berghella

Maruotti

et al.

Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: The PREGNANTS study. Am J Obstetrics Gynecology 2017; 216: 525–e1.

Galli

Luciani

Bertolini

Barbui

. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature. Blood 2003; 101: 1827–1832.

da Silva Saraiva

de Moraes Mazetto

Quinteiro Tobaldine

et al.

The impact of antibody profile in thrombosis associated with primary antiphospholipid syndrome. Am J Hematol 2017; 92: 1163–1169.

Rottenstreich

Arad

Terespolsky

et al.

Antiphospholipid antibody profile-based outcome of purely vascular and purely obstetric antiphospholipid syndrome. J Thromb Thrombolysis 2018; 46: 166–173.

Schreiber

Radin

Sciascia

. Current insights in obstetric antiphospholipid syndrome. Curr Opin Obstet Gynecol 2017.

10.

Pengo

Denas

Padayattil

et al.

Diagnosis and therapy of antiphospholipid syndrome. Pol Arch Med Wewn 2015; 125: 672–677.

11.

Axelsson O. Hemostasrubbningar inom obstetrik och gynekologi. Stockholm: SFOG; 2018.

12.

Grandone

Villani

Tiscia

. Aspirin and heparin in pregnancy. Expert Opin Pharmacother 2015; 16: 1793–1803.

13.

de Groot

Urbanus

. Antiphospholipid syndrome: Not a noninflammatory disease. Semin Thromb Hemost 2015; 41: 607–614.

14.

Meroni

Raschi

Grossi

et al.

Obstetric and vascular APS: same autoantibodies but different diseases?

Lupus 2012; 21: 708–710.

15.

Mayer-Pickel

Eberhard

Lang

Cervar-Zivkovic

. Pregnancy outcome in women with obstetric and thrombotic antiphospholipid syndrome: A retrospective analysis and a review of additional treatment in pregnancy. Clin Rev Allergy Immunol 2017; 53: 546–7.

16.

Socialstyrelsen. Statistikdatabas för graviditeter, förlossningar och nyfödda [Internet] Stockholm: Socialstyrelsen; 2017 [Available from: http://www.socialstyrelsen.se/statistik/statistikdatabas/graviditeter-forlossningarochnyfodda.

17.

Geblod.nu. Om blod och blodgrupper [Internet] Stockholm, Sweden: Geblod.nu; 2018-12-03 [Available from: https://geblod.nu/blodochblodgrupper/.].

18.

Taraborelli

Reggia

Dall'Ara

et al.

Longterm outcome of patients with primary antiphospholipid syndrome: A retrospective multicenter study. J Rheumatol 2017; 44: 1165–1172.

19.

Jeremic

Stefanovic

Dotlic

et al.

Neonatal outcome in pregnant patients with antiphospholipid syndrome. J Perinat Med 2015; 43: 761–768.

20.

Bramham

Hunt

Germain

et al.

Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus 2010; 19: 58–64.

21.

Rezk

Dawood

Badr

. Maternal and fetal outcome in women with antiphospholipid syndrome: A three-year observational study. J Matern Fetal Neonatal Med 2016; 29: 4015–4019.

22.

Latino

Udry

Aranda

Wingeyer

Romero

DSF

de Larranaga

. Pregnancy failure in patients with obstetric antiphospholipid syndrome with conventional treatment: The influence of a triple positive antibody profile. Lupus 2017; 26: 983–988.

23.

Girardi

Redecha

Salmon

. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10: 1222–1226.

24.

Berman

Girardi

Salmon

. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005; 174: 485–490.

25.

Gysler

Mulla

Guerra

et al.

Antiphospholipid antibody-induced miR-146a-3p drives trophoblast interleukin-8 secretion through activation of Toll-like receptor 8. Molecular Human Reproduction 2016; 22: 465–474.

26.

Schramm

Clowse

. Aspirin for prevention of preeclampsia in lupus pregnancy. Autoimmune Dis 2014; 2014: 920467.

27.

Erkan

Salmon

. The role of complement inhibition in thrombotic angiopathies and antiphospholipid syndrome. Turk J Haematol 2016; 33: 1–7.

28.

Duley

Henderson-Smart

Meher

King

. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007; 2: Cd004659.

29.

Baghaei F, Berntorp E, Edlund M, et al. Hemostasrubbningar inom obstetrik och gynekologi. Hjertberg R, Wegnelius G, Östlund E, editors. Stockholm: Svensk förening för Obstetrik och Gynekologi; 2012.

30.

Chighizola

Ubiali

Meroni

. Treatment of thrombotic antiphospholipid syndrome: The rationale of current management-an insight into future approaches. J Immunol Res 2015; 2015: 951424.